Home Page

NEW YORK, Oct. 24, 2016 /PRNewswire-iReach/ -- Reproductive Medicine Associates of New York (RMA of New York), a leading Manhattan-based fertility center, presented data from a retrospective cohort and case control study analyzing the relationship between the transfer of embryos deemed "poor quality" by morphological grading, and the potential impact on gestational age at delivery and infant birthweight.

The study reviewed a total of 420 frozen single embryo transfer cycles resulting in a live singleton birth and found no association between embryo morphokinetics and adverse perinatal outcome.

Lucky Sekhon, MD, the first author of the study and a fellow in Reproductive Endocrinology and Infertility at the Icahn School of Medicine at Mount Sinai Hospital, commented:

"We were able to demonstrate that embryos deemed "poor quality" by morphologic grading were not associated with a decrease in gestational age or birthweight at delivery. It is possible that by adopting a strategy of biopsy, freezing, and thawing embryos, we are able to synchronize the embryo and the endometrium, optimizing the implantation of developing blastocysts."

Cycles were stratified based on the Gardner-Schoolcraft grading system for blastocyst expansion, inner cell mass and trophectoderm. Patient age, BMI, endometrial thickness at transfer, gestational age at delivery and neonatal birthweight were recorded, and student's t-test, chi-square and linear regression were used for analysis. Patients were stratified into birthweight categories (low birthweight and macrosomia) and a binary logistic regression was used to identify whether morphokinetic factors were predictive of either outcome.

The study is one of 33 scientific abstracts that were presented by the renowned center at this year's ASRM, where the RMA of New York team of fertility experts gathered to share progressive data trailblazing the field of reproductive medicine.

Press interviews with RMA of New York can be arranged through Victoria Andretta, Director of Marketing (212-756-5777), vandretta@rmany.com.

About Reproductive Medicine Associates of New York, LLP

Reproductive Medicine Associates of New York (RMA of New York) is a national and international leader in state-of-the-art, compassionate reproductive medicine. The integrated team of physicians and scientists at RMA of New York has extensive experience and training in reproductive endocrinology, fertility, and urology, and consistently reports high success rates to the Society for Assisted Reproductive Technology (SART) and the Centers for Disease Control and Prevention (CDC). RMA of New York's achievements in the treatment of infertility have been internationally recognized, and the group maximizes access to care by assisting patients in exploring all available insurance coverage and financing options. RMA of New York has been recognized for its sensitivity to the LGBT community, women choosing single or same-sex motherhood, and women pursuing fertility preservation for elective and medical indications, including those in need of oncofertility services.

Headquartered in Midtown Manhattan, RMA of New York has three patient care facilities in Manhattan, as well as offices in Brooklyn, Garden City, and White Plains, NY. Additionally, RMA of New York has patient care facilities in Mexico City, Mexico. For more information, visit www.rmany.com.

Media Contact: Victoria Andretta, Reproductive Medicine Associates of New York, 2127565777, vandretta@rmany.com

Media Contact: Victoria Andretta, Reproductive Medicine Associates of New York, 212-756-5777, vandretta@rmany.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Reproductive Medicine Associates of New York